Preparation of and Clinical
Triethylene tetramine is the only therapeutic alternative for patients suffering from Wilson's disease who are intolerant of D-penicillamine. We report an improved method of preparation and an example of a successful course of treatment. D-penicillamine (DPA) has, since its introduction by Walshe in 1956, remained the drug of choice for the treatment of Wilson's disease.
Intolerance of DPA is rare in this condition and may be rarer than in other diseases for which the drug is also used. In Wilson's disease the treatment has to be continued in spite of various minor side-effects: gastrointestinal, allergic, cutaneous of several sorts, and others. They are either transient or overcome by adjustment of dosage or temporary addition of corticosteroids. The most prominent, though not the only cause Table 1 Comparative methods of preparing TETA 2HCI of absolute intolerance, is the induction of the nephrotic syndrome, the result of immunecomplex nephritis. Other contraindications to the continued administration of DPA are thrombocytopenia and leukopenia, drug-induced lupus erythematosus, myasthenia, oral ulceration and rheumatoid-like reaction (Walshe 1969) . Fortunately in many instances, carefully monitored reinstitution of the drug with or without corticosteroids, after a period of interruption, is possible without reappearance of the symptoms.
In those cases where several attempts at reinstitution are followed by recurrence of dangerous side-effects, the clinician is faced with a therapeutic dilemma. Other chelating agents (e.g. BAL) are of little value (Vaughan & Kaderbhai 1975 , Gibbs & Walshe 1975 for the treatment of Wilson's disease (British Medical Journal 1971) and there was no real substitute until 1969 when Walshe introduced a new chelating agent, triethylene tetramine dihydrochloride (TETA).
Several procedures for the preparation ofTETA have been described (Dixon et al. 1972 , Dubois et al. 1970 , Bucur & Hasselgren 1975 . In all of them TETA 'technical grade' is purified by transformation into the hydrochloride and fractional precipitation from a watery ethanolic solution. All these methods include evaporation of the solution into a syrup. Dixon, Gibbs & Walshe (197. Steps Purity Penicillamine Their reproducibility is limited because the yield and the HCl-content of the end product depend on the concentration of this syrup. When we followed these methods, we obtained products containing 2.3-3.2 mol HCI per mol TETA. Sufficiently pure TETA can be obtained only by repeated recrystallization from ethanol.
We should like therefore to describe a simpler procedure which permits preparation of a very pure TETA 2HCI in reproducible yields. Table 1 shows the detailed steps of our working protocol in comparison with the methods cited above. The properties of the product resulting from the respective methods of preparation are also listed in Table 1 .
Method
Raw base TETA technical grade 'Fluka', 100 ml, which contains 70 % TETA and three other fractions of 3 %, 18 % and 9 % respectively, is dissolved in 265 ml of diisopropyl ether and 35 ml of ethanol. At a temperature of 0°-10°C, 30 ml of 20% ethanolic HCI is added drop by drop with continuous stirring. The oily fluid which separates crystallizes within 10-15 min and yields 17-19 g of a hydrochloride consisting of one of the three impurity fractions plus traces of TETA. Then in the course of a further 30-45 min another 150 ml of ethanolic HCI is added drop by drop at 0°-10°. After 15 minutes the salt is filtered, then suspended in 200 ml of ethanol, filtered again, then washed in a mixture of diisopropyl ether and ethanol 1:1, and finally in diisopropyl ether. After vacuum desiccation at 50°-60°, 74-79 g (70-75 %) TETA 2HCl is obtained. Table 2 shows the results of an analysis by gas chromatography. A specimen alkalized with sodium methylate exhibits a degree of purity of 99.6 % with a melting point of 1 18°-122°.
Case Report
We report the successful treatment of a patient suffering from Wilson's disease who developed the nephrotic syndrome on penicillamine. W S, born 1947, housewife with a son born in 1968. She had no history of liver disease or jaundice. At the beginning of 1973 her illness began, with increasing tremor of the hands extending to the legs. She became unable to work or walk, and by the end of 1973 she was totally incapacitated. The diagnosis of Wilson's disease was made and treatment with D-penicillamine was instituted, with a maximum dosage of 3.0 g/day, later reduced to 2.4 g/day. One year later, when no satisfactory improvement of the neurological symptoms had taken place, proteinuria up to 12% developed, and DPA was withdrawn. The total dose of DPA administered amounted to 960 g. From 21 March till her admission to our Immunohistology: the glomeruli show a fine granular fluorescence with anti-IgG and anti-C3 as well as anti-IgM at the epithelial side of the basal membrane. These findings are characteristic of penicillamine nephropathy (Dr Henningsen, Hamburg).
After administration of 1.8 g of TETA/day the copper excretion in the urine rose to 149-239 ,ug/day, and the serum copper temporarily rose to 39 ,ug/100 ml. By November 1975 the neurological symptoms had improved considerably, though the liver copper had remained unchanged with 380, 248 and 461 ,ug/g dry weight. Antinuclear antibodies persisted, but proteinuria had diminished to 1 %. Urea and creatinine clearance were normal throughout. By March 1976 the patient had again become able to take care of her household. Cooking, sewing, writing and speech were nearly normal. The Kayser-Fleischer rings had almost disappeared, but urine copper excretion remained in the same order of magnitude, between 228 and 280 ,ug per 24 h. There was no proteinuria, but antinuclear antibodies still persisted. Fig 1 shows the considerable improvement in her handwriting.
Discussion
TETA has definite copper chelating properties, but there are obvious pharmacokinetic differences between TETA and penicillamine as I1I 10.6.1975 . 5.8.1975 17.11. 1975 P 15.3.1976 &^fw 12.4.1976 shown by their effects on the serum copper profile, copper mobilization and excretion (Walshe 1973) . Its mode of action remains to be elucidated. From the clinical point of view it is important to stress that the pure product is well tolerated. No toxicity has so far been noted (Walshe 1970 , Dubois et al. 1970 , Gelmers et al. 1973 . TETA is able to induce and maintain a negative copper balance, though the size of the cupruresis, especially after effective 'decoppering', is rather limited as compared with equimolar amounts of D-penicillamine. TETA represents the only satisfactory therapeutic substitute for penicillamine in the management of Wilson's disease.
The vital need for a particular drug, for which so far there is no other indication, for an extremely small group of patients representing a sub-fraction of sufferers of a rare disease, poses fundamental ethical, administrative, commercial and medicolegal problems. At the present time we know for certain of a total of only 13 patients reported in the literature as being under continuous treatment with TETA, including our own. The working capacity of a single clinical scientist is over-extended if he has no other choice but to prepare the compound himself in his laboratory for his patient, as Walshe has admirably done for years.
Undoubtedly Walshe and a few others, including ourselves, have created a demand which will increase, though remaining extremely small in absolute terms. TETA, though desperately needed by a few, is an 'orphan drug', promising no profit for a possible manufacturer and almost devoid of any hope of passing all the testing required for official approval for therapeutic application, even with a strictly limited indication as suggested by Scheinberg (1975) .
Who will take the legal risk of administering an unapproved drug when something unexpected may happen? This is a challenge for administrations, pharmaceutical companies and doctors, posing a number of unanswered questions recently discussed in the literature (Lyle 1975 , Peterson & Cerami 1975 , Scheinberg 1975 , Walshe 1975 , Lancet 1974 . We have approached the problem with the generous help of a company (Beiersdorf), simplifying the procedure and improving the quality and output of the drug.
